Student Research Committee, Nutrition Research Center, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Pharmacol Res. 2020 Jun;156:104770. doi: 10.1016/j.phrs.2020.104770. Epub 2020 Mar 23.
The effects of oleoylethanolamide (OEA) on NAFLD are yet to be examined in human. The objective of the present study was to examine the effects of OEA supplementation along with weight loss intervention on the expression of PPAR-α, uncoupling proteins 1and 2 (UCP1 and UCP2) genes in the peripheral blood mononuclear cells (PBMCs), metabolic parameters, and anthropometric indices among obese patients with NAFLD. In this triple-blind placebo-controlled randomized clinical trial, 76 obese patients newly diagnosed with NAFLD were randomly allocated into either OEA or placebo group along with calorie-restricted diets for 12 weeks. At pre-and post-intervention phase, mRNA expression levels of PPAR-α, UCP1, and UCP2 genes in the PBMCs, serum levels of metabolic parameters as well as diet and appetite sensations were assessed. There was a significant increase in the expression levels of PPAR-α, UCP1, and UCP2 genes in the PBMCs, compared to the placebo at the endpoint. A significant decrease in the anthropometric indices, energy and carbohydrate intakes, glycemic parameters, except for hemoglobin A1c concentration was also observed in the OEA group, compared to the placebo group. OEA treatment significantly resulted in decreased serum levels of triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALT/AST, increased serum levels of high-density lipoprotein cholesterol (HDL-C), and improved appetite sensations. Importantly, a significant improvement in TG, ALT, AST, ALT/AST, HDL-C levels as well as appetite sensations by OEA were under the influence of body mass index (BMI). Although liver steatosis severity was significantly reduced in both groups, the between-group differences did not reach statistical significance (P = 0.061). In conclusion, the present study, for the first time, revealed that OEA supplementation significantly improved anthropometric and metabolic risk factors related to NAFLD.
奥利诺酸乙酯（OEA）对非酒精性脂肪性肝病（NAFLD）的影响尚未在人体中进行研究。本研究的目的是检测 OEA 补充剂与减肥干预联合使用对肥胖合并 NAFLD 患者外周血单个核细胞（PBMC）中过氧化物酶体增殖物激活受体-α（PPAR-α）、解偶联蛋白 1 和 2（UCP1 和 UCP2）基因表达、代谢参数和人体测量学指标的影响。在这项三盲安慰剂对照随机临床试验中，76 名新诊断为 NAFLD 的肥胖患者被随机分为 OEA 或安慰剂组，并接受限制热量饮食 12 周。在干预前和干预后阶段，评估了 PBMC 中 PPAR-α、UCP1 和 UCP2 基因的 mRNA 表达水平、血清代谢参数水平以及饮食和食欲感觉。与安慰剂组相比，干预结束时 PBMC 中 PPAR-α、UCP1 和 UCP2 基因的表达水平显著增加。与安慰剂组相比，OEA 组的人体测量学指标、能量和碳水化合物摄入量、血糖参数（除血红蛋白 A1c 浓度外）均显著下降。OEA 治疗可显著降低血清甘油三酯（TG）、丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、ALT/AST、升高高密度脂蛋白胆固醇（HDL-C）水平，并改善食欲感觉。重要的是，OEA 可显著改善 TG、ALT、AST、ALT/AST、HDL-C 水平和食欲感觉，这与体重指数（BMI）有关。虽然两组肝脂肪变性严重程度均显著降低，但组间差异无统计学意义（P=0.061）。总之，本研究首次表明，OEA 补充剂可显著改善与 NAFLD 相关的人体测量学和代谢危险因素。
